Furthermore, c‐Abl is reported with multiple mutations in NSCLC patients and these mutants display more potent oncogenic activity,7 we thus next evaluated the ubiquitination on c‐Abl mutants by USP7. This evidence concerns the gene ABL1 and non-small cell lung carcinoma.